Month: October 2026

Unify full-funnel strategies—from CTV reach to digital conversions—in one platform with AI-powered workflows, greater transparency, and open MCP integrations

NEW YORK, Oct. 29, 2026 (GLOBE NEWSWIRE) — Teads (NASDAQ: TEAD), the omnichannel outcomes platform, today announced the launch of the next generation of Teads Ad Manager (TAM), its unified, end-to-end advertising platform. The platform evolution is designed to help agencies and advertisers connect campaigns across connected TV (CTV) and digital environments, understand campaign impact across the funnel, extend performance across quality media placements, and work more efficiently through AI-assisted workflows.

As daily media consumption reaches an all-time high of 13 hours and 26 minutes per day, and streaming accounts for the majority of television viewership, consumer journeys have become increasingly cross-screen. Despite this shift, media planning, buying, and reporting remain heavily fragmented across disconnected tools, with 53% of marketers struggling to unify measurement across channels for optimization. The latest evolution of TAM solves this by uniting Teads’ premium global supply across CTV and digital with full-funnel measurement and AI workflows. TAM users can seamlessly connect media investments across screens, measure total campaign impact, and work smarter using their preferred AI tools.

“Marketing teams and agencies can no longer afford to manage brand and performance in isolated silos if they want to drive real business growth,” said Remi Cackel, Chief Product Officer at Teads. “By connecting the omnichannel journey in one platform and enabling AI-powered workflows, we’re giving our partners the control, efficiency, and intelligence needed to make every media investment deliver measurable impact.”

“Agencies require technology that simplifies media execution without compromising supply quality or data flexibility,” said Rheece Hemmings, Programmatic Manager at OMD, UK. “TAM’s connected toolset and open AI architecture allow our teams to plan, activate, and optimize cross-screen campaigns in minutes, giving us full visibility into how branding and performance work together to drive client growth.”

Key Platform Innovations
The next evolution of TAM introduces four key platform capabilities:

• Omnichannel Strategies & Full-Funnel Measurement: Activate campaigns against multiple KPIs across CTV and digital within a single workflow and measure how upper-funnel brand activity drives lower-funnel outcomes—like tracking site visits generated by branding campaigns.
• Unified Performance: Extend performance campaigns seamlessly across CTV and digital—including CTV InStream, HomeScreen, inRead, and Feed placements. Access premium, transparent media supply with built-in quality controls and flexible measurement integrations, including Conversion API (CAPI) and Google Analytics 4 (GA4).
• Agentic AI Workflows: Automate campaign planning, setup, management, and reporting with task-specific AI copilots. Go from brief to strategy with Strategy Builder or catch delivery and pacing risks instantly in Control Hub—slashing troubleshooting time from 15 minutes to under 60 seconds.¹
• Open Model Context Protocol (MCP) Interconnectivity: Connect Teads’ audience insights, reach forecasting, and inventory discovery directly into agency AI systems, including Claude, Gemini Enterprise, and Microsoft Copilot, through open, secure MCP integrations.

“MCP is really a game changer because it gives us exactly what we need from discovery through to campaign creation,” said Nami Hamidi, Head of Precision at Havas Media Network Italy. “It combines different data sources with TAM’s knowledge and data to help create the best strategy and media plan, with recommendations on audiences, websites, context and creatives, as well as estimates for CPMs and CTRs.”

Teads is also expanding its Teads Ad Manager Certified Agency Program. This global platform accreditation program provides agency teams with structured training in omnichannel media, performance advertising, and strategic planning. Certified partners gain priority beta access and industry recognition for their platform expertise.

Availability
Unified Performance capabilities are generally available to global enterprise clients today. Full-Funnel Measurement, Strategy Builder, Control Hub, and MCP integrations are currently available in closed beta to TAMbassadors, with broader global access planned through the end of 2026.

To request a platform demonstration, beta access, or learn more about Teads Ad Manager, visit https://www.teads.com/lp/teads-ad-manager/ or contact your Teads representative.

Sources
¹ Alpha Test Results (2026): In-platform AI assistant testing.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws, which statements involve substantial risks and uncertainties. Forward-looking statements generally relate to possible or assumed future results of our business, financial condition, results of operations, liquidity, plans and objectives. You can generally identify forward-looking statements because they contain words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “guidance,” “outlook,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “foresee,” “potential” or “continue” or the negative of these terms or other similar expressions that concern our expectations, strategy, plans or intentions.

We have based these forward-looking statements largely on our current expectations and projections regarding future events and trends that we believe may affect our business, financial condition and results of operations. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties and other factors, including but not limited to: the risk that the new capabilities of Teads Ad Manager, including AI-powered workflows and Open MCP integrations, may not perform as expected, launch on the anticipated timeline, or achieve expected market adoption; the highly competitive nature of the digital, CTV, and streaming advertising markets; and the other important risks described in the section entitled “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed for the year ended December 31, 2025, and our Quarterly Reports on Form 10-Q filed for the quarters ended March 31, 2026, and June 30, 2026, filed with the Securities and Exchange Commission (the “SEC”), which are available on our website at https://investors.teads.com/ and on the SEC’s website at www.sec.gov.

Accordingly, you should not rely upon forward-looking statements as predictions of future events. We cannot assure you that the results, events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results, events or circumstances could differ materially from those projected in the forward-looking statements. We undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

About Teads
Teads Holding Co. (“Teads”) (Nasdaq: TEAD) is a leading omnichannel advertising platform focused on driving outcomes for brand and performance advertisers across screens. With a focus on meaningful business outcomes for full funnel objectives, Teads drives value by leveraging predictive AI technology to connect quality media, beautiful brand creative, and context-driven addressability and measurement. Teads is directly partnered with more than 10,000 publishers and 20,000 advertisers globally. The company is headquartered in New York, New York, with a global team of around 1,700 people in 30+ countries.

For more information, visit www.teads.com.

Media Contact

press@teads.com

Investor Relations Contact

IR@teads.com

(332) 205-8999

Study Reports Immediate Pain Freedom in 14 of 15 Patients; all Patients Achieved Favorable Pain Outcomes at a Mean Six-Month Follow-Up

Multi-Contact Probe Technology Enabled Mapping and Treatment of Trigeminal Nerve Distributions without Repeated Probe Repositioning

EDEN PRAIRIE, Minn., Oct. 29, 2026 (GLOBE NEWSWIRE) — NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on the surgical diagnosis and treatment of neurological disorders, today announced the publication of initial clinical results evaluating its OneRF^® Trigeminal Nerve Ablation System in the peer-reviewed journal Pain Management.

The article, “OneRF radiofrequency ablation system for the minimally invasive treatment of trigeminal neuralgia: initial clinical experience,” was published online in October 2026. Authored by Michael D. Staudt, Theresa A. Elder, Marshall T. Holland and David P. Darrow, the retrospective study evaluated 15 patients with medically refractory trigeminal neuralgia treated during the system’s limited market release.

Trigeminal neuralgia causes sudden, severe, electric shock–like facial pain that can interfere with eating, speaking, and other daily activities. For patients whose pain cannot be adequately controlled with medication, percutaneous radiofrequency ablation of the trigeminal nerve offers a minimally invasive treatment option.

Conventional radiofrequency systems typically use a single active tip that must be repositioned to map and treat different trigeminal nerve distributions. OneRF’s thin-film, multi-contact probe allows physicians to perform multiple contact-level mapping and lesioning along a single fixed trajectory without repositioning. The lack of needing to reposition the probe may allow for reduced procedure times, lower number of anesthesia cycles and, most importantly, less discomfort for the patient during the procedure.

Key findings from the published study include*:

• Immediate pain freedom in 93.3% of patients: Fourteen of fifteen patients were pain-free immediately after treatment. The remaining patient experienced partial initial relief and became pain-free approximately one week later.
• Favorable outcomes at follow-up: All 15 patients achieved a good clinical outcome, defined as a Barrow Neurological Institute pain score of I–IIIB, at a mean follow-up of six months.
• Pain freedom without medication: Eight patients, or 53.3%, were pain-free and taking no pain medication at their last follow-up. Six additional patients were pain-free while continuing medication; one had residual pain controlled with medication.
• Mapping and treatment along a fixed trajectory: Contact-level mapping was achieved in every case, and no patient required probe repositioning to map and treat multiple trigeminal distributions.
• No observed off-target lesioning: The authors reported no off-target lesioning, ophthalmic complications, or anesthesia dolorosa.
• Complications: One patient developed a cheek hematoma during needle insertion and repositioning, which was treated with ice and resolved after 1 week; this same patient also developed transient masseter weakness.

“Treating trigeminal neuralgia requires careful localization of the nerve distributions responsible for each patient’s pain,” said Michael D. Staudt, MD, lead author of the publication. “In this initial series, the multi-contact probe allowed us to map and treat those distributions along a single fixed trajectory. The early pain outcomes are encouraging, and longer follow-up will help us understand the durability of relief.”

Dave Rosa, President and Chief Executive Officer of NeuroOne, added, “This publication adds peer-reviewed clinical evidence to our experience with OneRF for trigeminal neuralgia. We are encouraged by the pain relief reported in this initial cohort and by the ability to map and treat multiple nerve distributions without repeated probe repositioning. These findings support continued adoption of the platform and its potential to simplify the treatment workflow.”

The authors emphasized that this was a small, retrospective series without a direct comparison group. Larger studies and longer follow-up are needed to establish long-term durability, comparative effectiveness, and the contribution of contact-specific mapping to patient outcomes.

The publication is available at: https://doi.org/10.1080/17581869.2026.2748288.

About the OneRF^® Trigeminal Nerve Ablation System

The OneRF^® Trigeminal Nerve Ablation System leverages NeuroOne’s proprietary radiofrequency ablation technology and features a multi-contact probe designed to enable stimulation, mapping and ablation during trigeminal neuralgia procedures. The system is designed to streamline procedural workflow by potentially reducing the number of probe repositioning and anesthesia cycles while providing physicians with temperature-monitored radiofrequency ablation.

The NeuroOne OneRF^® Trigeminal Nerve Ablation System is indicated for use in procedures to create radiofrequency lesions for the treatment of pain, or for lesioning nerve tissue for functional neurosurgical procedures.

About NeuroOne

NeuroOne Medical Technologies Corporation is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders. NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF^® Ablation System (for brain), and OneRF^® Trigeminal Nerve Ablation System.

NeuroOne has also developed the StereoCED™ platform for targeted intracranial drug delivery, which is currently available for animal research and approved investigational clinical studies. StereoCED™ has not been cleared or approved by the FDA or any other regulatory agency. These solutions offer the potential to reduce the number of hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering diagnostic and therapeutic functions. The Company is engaged in research and development for basivertebral nerve ablation and spinal cord stimulation programs. For more information, visit nmtc1.com.

Forward Looking Statements

This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this press release may be a forward–looking statement that reflects NeuroOne’s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words or phrases “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue, “focused on,” “committed to” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding patient outcomes and the potential for lower procedure times, lower number of anesthesia cycles and less discomfort for the patient during the procedure. The distribution agreement does not provide for any guaranteed purchase orders, minimum purchase commitments or guaranteed sales, and there can be no assurance as to the level of sales, if any, that will be generated under the arrangement. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that our partnerships may not facilitate the commercialization or market acceptance of our technology; risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials; risks related to uncertainties associated with the Company’s capital requirements to achieve its business objectives and ability to raise additional funds; the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology; uncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements or decisions of regulatory authorities; that we may not have accurately estimated the size and growth potential of the markets for our technology; risks related to our ability to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.

Clinician disclosure: Drs. Staudt, Holland and Darrow disclosed consulting relationships with NeuroOne. The publication reported no funding for the paper.

* Disclaimer: This recounts several patients’ experiences and may not be representative of all patient outcomes.

Caution: Federal law restricts this device to sale by or on the order of a physician.

Company Contact:
800-631-4030
ir@nmtc1.com

Investor Relations:
MZ Group – MZ North America
949-491-8235
NMTC@mzgroup.us

Maria Maccecchini, PhD, CEO of Annovis, will join industry panel with pharma leaders and present company updates

MALVERN, Pa., Oct. 29, 2026 (GLOBE NEWSWIRE) — Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that Maria Maccecchini, PhD, Founder, President and CEO of Annovis, will participate and present in two industry events in November.

U.S. Biotech Day 2026 | November 16–17, 2026 | Philadelphia, PA

• Panel: “Bridging the Translational Gap: From Discovery Insights to Clinical Proof”, November 16, 9:15–9:45 a.m. ET
• Company showcase: November 16, 10:15–10:30 a.m. ET

At U.S. Biotech Day 2026, Dr. Maccecchini will join a panel of leaders from Pfizer, Merck, Bristol Myers Squibb, Boehringer Ingelheim and other pharmaceutical companies to discuss how discovery-stage insights translate into clinical proof. She will also deliver a company presentation highlighting Annovis’ clinical programs and upcoming milestones.

Pharma Partnering Summit 2026 | November 19–20, 2026 | Boston, MA

• Company presentation: “Restoring Proteostasis in Alzheimer’s and Parkinson’s Diseases with Buntanetap, a Translational Inhibitor of Neurotoxic Proteins”, November 19, 11:25–11:55 a.m. ET

At Pharma Partnering Summit 2026, Dr. Maccecchini will present Annovis’ clinical progress and meet with biotech and pharma representatives.

During both events, Dr. Maccecchini will also hold one-on-one meetings with industry leaders. Attendees interested in scheduling a meeting may do so through each event’s partnering system or by contacting us at ir@annovisbio.com.

About Annovis
Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The Company’s lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.

Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.

Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com

Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com

Media Release

• Immutep intends to focus the registration-directed clinical development of efti on HNSCC in patients with CPS <1 and the neoadjuvant setting of STS, with preparations for future clinical trials underway and study start targeted for H2 CY27.
• IMP761, the Company’s agonist anti-LAG-3 antibody for autoimmune diseases, is now a co-priority alongside efti and will be the subject of a late breaking poster at the American College of Rheumatology (ACR) Convergence in November 2026.
• The ongoing root cause analysis following the discontinuation of TACTI-004 has identified structural differences between the 2000 L scale efti used in TACTI-004 and the 200 L scale efti used in earlier successful clinical studies. A new manufacturing run of efti at 200 L scale has been contracted.
• The Company received an A$0.86 million cash rebate under the Australian Government’s R&D Tax Incentive for eligible FY2025 R&D activities and, subsequent to the end of the quarter, €1.36 million (approximately A$2.16 million) from the French Government under its Crédit d’Impôt Recherche (CIR) program for eligible CY2025 R&D activities.
• Cash and term deposits of A$48.50 million at 30 September 2026, with cash runway expected to extend well into H1 CY28.

SYDNEY, AUSTRALIA, Oct. 29, 2026 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, provides an update on its activities for the quarter ended 30 September 2026 (Q1 FY27).

EFTILAGIMOD ALFA DEVELOPMENT PROGRAM FOR CANCER

TACTI-004 (KEYNOTE-F91) – Phase III Trial in 1L NSCLC

Following the early discontinuation of the TACTI-004 study, Immutep has been conducting a detailed root cause analysis.

In September, Immutep announced that the ongoing root cause analysis identified structural differences between the efti used in TACTI-004 and the efti used in earlier successful clinical studies. These differences (e.g. a subtle difference in N-glycan structure) are considered potentially relevant given the markedly different immune activation profile observed in TACTI-004 compared to previous trials and the unexpected clinical outcome of the study.

Based on the currently available data from the root cause analysis to date, Immutep believes that the unexpected outcome of TACTI-004 cannot be explained by clinical factors (e.g. suboptimal protocol, substantial imbalance between treatment arms or safety findings) or trial execution factors (e.g. invalid randomisation pattern or general clinical trial conduct).

The Company will provide a further update on the root cause analysis at its Annual General Meeting on 27 November 2026.

New Manufacturing Run

Based on the findings from the root cause analysis to date, Immutep has contracted a manufacturing run of efti at 200 L scale. Ten GMP batches of efti have previously been manufactured at 200 L scale and used in successful Phase I and Phase II clinical studies of efti, including TACTI mel, TACTI-002 and INSIGHT-003. In contrast, TACTI-004 was conducted exclusively with efti manufactured at 2,000 L scale.

Future Clinical Development Focus

Immutep currently intends to focus the potential registration-directed clinical development of efti on:

• HNSCC in patients with CPS <1; and
• the neoadjuvant setting of STS.

This focus reflects the compelling clinical data generated to date, the Company’s interactions with the FDA, regulatory designations obtained, unmet medical need and substantial market potential in these indications.

Preparations for the next phase of clinical trials have commenced. Subject to final decisions on strategy and trial design, regulatory interactions, manufacturing timelines, partnering and resources, Immutep is targeting study start during H2 CY27.

Immutep’s licensing partner, Dr. Reddy’s Laboratories (“DRL”), has been consulted on and is supportive of this approach. The Company is also in preliminary discussions with other parties regarding the proposed development pathway.

INSIGHT-003 – Phase I Trial in Non-Squamous 1L NSCLC

The investigator-initiated INSIGHT-003 Phase I trial has been completed.

In this study, the combination of efti with KEYTRUDA^® and chemotherapy has generated strong objective response rates (ORR) and disease control rates (DCR) in 51 evaluable patients with advanced or metastatic non-squamous 1L NSCLC across all PD-L1 expression levels.

As previously announced, mature overall survival (OS) results from INSIGHT-003 (data cut-off 27 March 2026) demonstrated a median overall survival (mOS) of 30.9 months in the overall study population.¹

These results compare favourably with historical benchmarks. No new safety signal was identified since the previous data cut-off.

EFTISARC-NEO – Phase II Trial in Soft Tissue Sarcoma

Immutep announced in September that one of the two indications in which it intends to focus the registration-directed clinical development of efti is the neoadjuvant setting of soft tissue sarcoma (STS).

The investigator-initiated EFTISARC-NEO Phase II trial evaluating efti in combination with radiotherapy and KEYTRUDA^® in the neoadjuvant setting for resectable STS has met its primary endpoint, with a median 51.5% tumour hyalinization/fibrosis in the evaluable population (N=38), significantly exceeding the prespecified 35% target (p<0.001). Patients also showed strong immune system activation in line with efti’s mode of action, including statistically significant increases in the expression of key cytokines and chemokines in peripheral blood. Patients are continuing to be followed up for disease-free survival.

Immutep also received Orphan Drug Designation for efti in this setting from the FDA in April 2026.

Subsequent to the end of the quarter, on 23 October 2026, Immutep announced health-related quality of life (HRQoL) data from the EFTISARC-NEO trial, presented in an ePoster at the ESMO Congress 2026 in Madrid. HRQoL, a secondary endpoint, remained stable during neoadjuvant treatment, with no statistically significant deterioration in any measured scale. After surgery, patients reported statistically significant improvements in the QLQ-C30 summary score (6.0 points; p=0.008) and in role and social functioning, and reported significantly lower fatigue than at baseline (by up to 14.2 points; p=0.001).

AIPAC-003 – Phase II Trial in Metastatic Breast Cancer

The AIPAC-003 Phase II trial evaluated efti in combination with chemotherapy in hormone receptor positive (HR+), HER2 negative/low metastatic breast cancer that is resistant to endocrine-based therapy, as well as in metastatic triple-negative breast cancer not eligible for PD-(L)1-based therapy. As previously announced, the trial closed effective 30 June 2026.

Investigator-Initiated Phase II Trial for Neoadjuvant Efti in HR+/HER2-Negative Breast Cancer

As previously announced, a proposed investigator-initiated Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in early-stage HR+/HER2-negative breast cancer remains on hold pending completion of the root cause analysis related to TACTI-004 and further strategic decisions.

IMP761 DEVELOPMENT PROGRAM FOR AUTOIMMUNE DISEASE

IMP761 – Phase I Trial

Development of IMP761, the Company’s agonist anti-LAG-3 antibody for autoimmune diseases, continues in line with previously disclosed plans and is now a co-priority alongside efti.

In June 2026, Immutep presented positive interim data from its placebo-controlled, double-blind, randomized, first-in-human Phase I study evaluating IMP761, a first-in-class LAG-3 agonist antibody, at the EULAR 2026 Congress in London.

The single ascending dose part of the study met its primary endpoint, demonstrating favourable safety and tolerability in healthy volunteers, with IMP761 well tolerated across all dose levels tested.

The data also showed statistically significant pharmacodynamic activity, including reduced local inflammatory responses and attenuated T-cell activity compared to placebo, with the 7 mg/kg dose achieving a statistically significant inhibition in skin blood perfusion (p = 0.029).

The pharmacokinetic profile supports once-every-four-weeks dosing. These encouraging results support further clinical evaluation of IMP761 in autoimmune diseases driven by T-cell-mediated inflammation, such as rheumatoid arthritis or type 1 diabetes, with additional trial updates expected at the American College of Rheumatology (ACR) Convergence 2026, taking place from 6 to 11 November 2026 in Orlando, Florida, USA. As announced on 19 October 2026, a late-breaking abstract on IMP761 has been accepted for poster presentation at the conference on 10 November 2026.

INTELLECTUAL PROPERTY

During the quarter, Immutep continued to build its patent estate and was granted three new patents.

In particular, as announced in July, Immutep was granted its fourth United States patent directed to efti in combination with a PD-1 pathway inhibitor.

The Company was also granted a Russian patent directed to IMP761 and an Australian patent directed to an assay used to measure the potency of IMP761 as part of a quality control step in the production of the agonist LAG-3 antibody.

CORPORATE AND FINANCIAL SUMMARY

Change to American Depositary Share Ratio

Following the Nasdaq minimum bid price deficiency notification announced on 30 April 2026, Immutep announced on 21 September 2026 a change to the ratio of its American Depositary Shares (ADSs), effective 28 September 2026 (US Eastern time), from one ADS representing 10 ordinary shares to one ADS representing 200 ordinary shares.

For holders of ADSs, the change has the same practical effect as a reverse split of the ADSs on the basis of one new ADS for every 20 ADSs held. The Company’s ordinary shares quoted on the ASX are not affected, the number of ordinary shares on issue does not change, and the change does not alter the proportionate economic interest of any shareholder or ADS holder in the Company.

Subsequent to the end of the quarter, on 13 October 2026 Immutep announced that it had received written notification from Nasdaq confirming that it had regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1), following a closing bid price at or above US$1.00 per ADS for 10 consecutive business days from 28 September 2026 to 9 October 2026. Nasdaq has advised that the matter is now closed.

Board and Audit and Risk Committee

Subsequent to the end of the quarter, Pete Meyers resigned as a Non-Executive Director effective 2 October 2026. As announced on 9 October 2026, following Mr Meyers’ resignation the Audit and Risk Committee comprises two members and the Company is not currently in compliance with ASX Listing Rule 12.7. The Board has commenced a search for an additional independent non-executive director with financial and accounting expertise who, once appointed, is intended to join the Audit and Risk Committee and be invited to chair it. The Company expects to complete the appointment during the financial year ending 30 June 2027. In the interim, Lis Boyce is acting as Chair of the Audit and Risk Committee. The Committee’s recommendations on financial reporting, accounting judgements and external audit continue to be referred to the full Board.

Cash Flow Summary

During the quarter, Immutep continued to exercise prudent cash management, particularly in light of the TACTI-004 Phase III discontinuation.

In September, Immutep announced it had received an A$0.86 million cash rebate under the Australian Government’s R&D Tax Incentive for eligible R&D activities conducted in FY2025. Following AusIndustry’s approval of an Advance Overseas Finding, certain of Immutep’s overseas R&D activities were eligible alongside its Australian activities.

Subsequent to the end of the quarter, on 28 October 2026, Immutep announced it had received a cash payment of €1.36 million (approximately A$2.16 million) from the French Government under its Crédit d’Impôt Recherche (CIR) research tax incentive program for eligible R&D activities conducted in calendar year 2025. Immutep is eligible for the CIR through its French subsidiary, Immutep S.A.S., which conducts research at its laboratory in France. As this payment was received after 30 September 2026, it is not included in the quarter-end cash and term deposits balance.

The non-dilutive funding from both incentives will be applied to Immutep’s current R&D activities for its product candidates, efti and IMP761. Immutep’s expected cash reach extends well into the first half of CY28.

The net cash used in G&A activities in the quarter was A$1.2 million compared to A$1.5 million in Q4 FY26.

In Q1 FY27, cash receipts from customers were A$6K, which is mainly due to research material sales. Net cash used in R&D activities was A$16.5 million for the quarter, compared with A$22.0 million in Q4 FY26, with the decrease primarily reflecting a decrease in clinical trial activity as the Company continued the close-out relating to TACTI-004. As invoices are generally payable approximately one month after issue, TACTI-004 payments are expected to decline significantly in subsequent quarters.

Payment for staff costs was A$2.4 million in the quarter, compared to A$2.5 million in Q4 FY26. Total net cash outflows used in operating activities in the quarter were A$19.1 million compared to net cash outflows of A$38.9 million in Q4 FY26.

Total net cash inflow received in investing activities for the quarter was A$5.0 million, which is mainly due to the transfer back of matured short-term investments to cash at bank. The short-term investments are comprised of term deposits with maturities of greater than 3 months and less than 12 months.

As at 30 September 2026, Immutep had total cash and term deposits of approximately A$48.50 million, comprising cash and cash equivalents of A$48.41 million and term deposits of A$0.09 million.

Payments to related parties and their associates of A$456K, comprises non-executive directors’ fees and executive directors’ remuneration.

After the TACTI-004 Phase III futility outcome, the Company has initiated cost reduction measures to preserve capital and extend its cash runway. These measures include a targeted reduction in headcount and other operating expense reductions, most of which took effect from the start of FY27. The discontinuation of TACTI-004 also precipitates a reduction in cash outlays due to the trial activity being wound down. At the time of preparing this report, the Company expects its cash runway to extend well into H1 of CY28.

About Immutep
Immutep is a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune diseases. The Company is a pioneer in the understanding and advancement of therapeutics related to the Lymphocyte Activation Gene-3 (LAG-3)/MHC Class II immune control mechanism, and its diversified product portfolio harnesses the ability of this mechanism to stimulate or suppress the immune system. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.

Forward Looking Statements
This announcement contains forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995, including statements regarding the ongoing root cause analysis relating to TACTI-004; the manufacture of efti at 200 L scale; Immutep’s intended clinical development focus for efti in HNSCC and STS, including the design, regulatory interactions and targeted start of future clinical trials; partnering discussions, including with DRL and other parties; the anticipated timing of further clinical updates for IMP761; expected reductions in TACTI-004 payments and other operating costs; and Immutep’s expected cash runway. Forward-looking statements can be identified by words such as “anticipate”, “believe”, “expect”, “intend”, “plan”, “target”, “potential”, “may”, “will”, “should” and similar expressions.

Forward-looking statements are based on Immutep’s current expectations and assumptions as at the date of this announcement and are subject to known and unknown risks, uncertainties and other factors, many of which are beyond Immutep’s control, that could cause actual results to differ materially from those expressed or implied. These include: the findings and timing of the root cause analysis, which is not complete and may not identify a conclusive cause for the outcome of TACTI-004; whether efti manufactured at 200 L scale will be comparable to efti used in earlier clinical studies, and the timing and success of the new manufacturing run; the results of ongoing and future clinical trials, which may not replicate earlier results; the requirements of the FDA and other regulators for future trials; Immutep’s ability to enter into partnering arrangements and the terms of any such arrangements; the actual timing and amount of TACTI-004 wind-down costs and other expenditure; the timing and amount of R&D tax incentives; Immutep’s ability to obtain additional funding; and the other risks described in Immutep’s filings with the ASX and the US Securities and Exchange Commission, including its most recent Annual Report on Form 20-F.

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this announcement. Except as required by law or the ASX Listing Rules, Immutep undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

1. Immutep press release – 13 July 2026

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Australian Investors/Media:
Eleanor Pearson, Sodali & Co.
+61 2 9066 4071; eleanor.pearson@sodali.com

U.S. Investors/Media:
Matthew Beck
Ph: +1 (917) 415-1750; matthew.beck@astrpartners.com

On-site mill services agreement continues long-standing relationship dating back to 1999

LONDON, Oct. 29, 2026 (GLOBE NEWSWIRE) — Harsco Environmental, a division of Enviri Corporation (NYSE: NVRI) and a global leader in providing innovative environmental solutions, today announced it has signed a 10-year contract renewal with EZS, a steel mill in Sadat City, Egypt, with a production capacity of one million tons of rebar per year.

Under the agreement, Harsco Environmental will provide furnace and scrap management services at the EZS site, which includes steel-making facilities such as an electric arc furnace, a billet caster, and two rolling mills. Harsco Environmental will help EZS maximize operational efficiency, recover valuable materials, and improve environmental performance.

“The renewal of this long-standing partnership demonstrates the strength of our collaboration with EZS and the value Harsco Environmental delivers to steel producers through safe, efficient, and sustainable mill services,” said Harsco Environmental’s Regional President of EMEA, Stéphane Boissinot. “This contract renewal both reinforces our regional presence and creates opportunities to drive future growth.”

EZS is owned by EZZ Steel, the leading steel producer in the Middle East and North Africa, with an average annual production of around 6.5 million tons. This is one of three contracts Harsco Environmental has with EZZ Steel. The Company also provides services to EZDK in Alexandria and to EFS in Sokhna, further supporting steelmaking operations across Egypt.

For more information about Harsco Environmental and its solutions, visit https://www.harsco-environmental.com.

About Harsco Environmental

Enviri’s Harsco Environmental division is the largest and most comprehensive provider of onsite material processing and environmental services to the global metals industry, with operations at over 130 customer sites across more than 32 countries. Harsco Environmental is a technology partner delivering cleaner, more efficient metal production, providing customers with economically and environmentally viable solutions for the treatment and reuse of production co-products. Visit harsco-environmental.com to learn more.

Investor Contact	Media Contact
David Martin	Karen Tognarelli
+1.267.946.1407	+1.717.480.6145
dmartin@enviri.com	ktognarelli@enviri.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a712ede4-b17f-4840-be2c-c539f2b4b057

$100 from every bottle sold will benefit Denver men’s ice hockey scholarships

DENVER, Oct. 29, 2026 (GLOBE NEWSWIRE) — Breckenridge Distillery, an award-winning craft distillery and subsidiary of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), and University of Denver Athletics today announced the release of a limited-edition Breckenridge Single Barrel Bourbon Whiskey celebrating the Denver Pioneers’ 2026 NCAA Men’s Ice Hockey National Championship.

The commemorative release celebrates Denver’s record 11th national championship while supporting the future of the program, with $100 from every bottle sold benefiting the Denver Men’s Ice Hockey Scholarship. The 230-bottle release was created from a special single barrel selected in collaboration with Denver Athletics supporters at Breckenridge Distillery and is bottled at 101.7 proof.

“Denver hockey’s tradition of excellence reflects the same values we bring to every bottle we make: dedication, craftsmanship and pride in representing Colorado at the highest level,” said Bryan Nolt, Founder and CEO of Breckenridge Distillery. “Having DU Athletics supporters join us in the barrel room to help select this whiskey made the process truly collaborative, and knowing the proceeds will support the next generation of Denver hockey players makes this release even more meaningful.”

The Pioneers captured their record 11th national championship on April 11, 2026, defeating Wisconsin in Las Vegas. Denver holds the all-time record with 11 national championships, including four in the past decade in 2017, 2022, 2024 and 2026. Under Richard and Kitzia Goodman Head Hockey Coach David Carle, Denver has captured its three most recent titles, delivering three championships in five years.

“Last spring’s 11th Denver hockey national championship, the program’s third title in five years, was a special moment in Denver Athletics history,” Vice Chancellor for Athletics and Ritchie Center Operations Josh Berlo said. “Special moments, especially ones of this magnitude, call for special commemoration. We are excited that a close group of supporters had the opportunity to provide input with Breckenridge Distillery and be a part of barrel tasting for this new product for our fans. To have a significant portion of the proceeds go towards hockey scholarships makes this a full circle commemoration and empowering future national success for the legacy and tradition that is Denver hockey.”

The collaboration brought a group of Denver Athletics supporters to Breckenridge Distillery for a behind-the-scenes experience in the barrel room. Participants toured the distillery, learned about the whiskey-making process and evaluated different barrels alongside the Breckenridge Distillery team before helping select the single barrel used for the commemorative release.

“We were welcomed with open arms at the Breckenridge distillery. They took us to a tasting area and provided us with the tools to evaluate different barrels and interact with each other and the staff,” said Tim Thompson, a University of Denver alumnus and DU Athletics supporter. “It was great fun to play a small role in this partnership between DU Athletics and Breckenridge Distillery.”

The limited-edition whiskey showcases Breckenridge Distillery’s grain-to-glass craftsmanship under the direction of Master Distiller Hans Stafsholt. Bottled at 101.7 proof, the single-barrel release offers aromas of balanced oak spice, caramel and brown sugar, followed by a creamy, viscous palate with notes of caramel, brown sugar and cinnamon and a hint of black pepper spice.

The 230-bottle limited release is available for $179.99 at Bonnie Brae Liquor, 785 S. University Blvd., Denver, Colorado, and Mondo Vino, 3601 W. 32nd Ave., Denver, Colorado. The bottle is also available for home delivery where permitted.

Age 21+. Always enjoy responsibly.

About Breckenridge Distillery
Founded in Colorado in 2008, Breckenridge Distillery is the “World’s Highest Distillery,” and is best known for its award-winning blended bourbon whiskey, a high-rye mash American-style whiskey. One of the most highly awarded distilleries in the U.S., the Breckenridge Distillery is proudly a 3x Icons of Whisky and 10x winner of Best American Blended at the World Whiskies Awards by Whisky Magazine and a 6x winner of Colorado Distillery of the Year by the New York International Spirits Competition. Most recently, Breckenridge Port Cask Finish was named World’s Best Finished Bourbon at the 2024 World Whiskies Awards, joining Breckenridge High Proof, named World’s Best Blended Whiskey, and Breckenridge Gin, named World’s Best Compound Gin at the World Gin Awards by Gin Magazine. Breckenridge spirits have been awarded 7 Double Golds at the San Francisco World Spirits Competition.

The Breckenridge Distillery is more than award-winning spirits, offering an immersive guest experience. Named one of the country’s Top Visitor Attractions by Whisky Magazine, guests can dine at the award-winning restaurant, enjoy show-stopping cocktails, explore an in-depth tasting, and get an inside look at the active production facility—including the opportunity to blend their own whiskey.

Breckenridge Distillery is a subsidiary of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life.

To learn more about Breckenridge Distillery, visit www.breckenridgedistillery.com. Keep up with Breckenridge Distillery on Instagram by following @breckdistillery and become a fan at facebook.com/BreckDistillery. For more information about Tilray Brands, visit www.tilray.com and follow @tilray on Instagram, Twitter, Facebook, and LinkedIn.

About Tilray Brands 
Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods and craft beverages. 

For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms. 

Forward-Looking Statements
 Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian and U.S. securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.

For further information, please contact
Media: Breckenridge@klgpr.com, 970-771-3662
Tilray Brands Media: news@tilray.com
Investors: investors@tilray.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/133f4f69-7534-4939-8016-37e62e96f13a

JERSEY CITY, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced that the SCYNEXIS senior leadership team will participate in the 3rd Annual Guggenheim Healthcare Innovation Conference, taking place November 9-11, 2026, in Boston.

One-on-One Meetings
Dates: November 9-10, 2026

Fireside Chat
Date: Monday, November 9, 2026
Time: 2:30 p.m.-3:00 p.m. ET

A live webcast of the Guggenheim fireside chat will be available here. A replay of the webcast will be available on our website for 90 days following the event.

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ: SCYX) is a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases. SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. SCYNEXIS’s proprietary antifungal platform “fungerps” includes BREXAFEMME® (ibrexafungerp tablets), the first approved representative of this novel class, which has been licensed to GSK, and SCY-247, currently in clinical stages of development for the treatment and prevention of invasive fungal diseases. For more information, visit www.scynexis.com.

CONTACT:
Investor Relations
John Fraunces
LifeSci Advisors
Tel: 917-355-2395
jfraunces@lifesciadvisors.com

GREENWICH, Conn., Oct. 29, 2026 (GLOBE NEWSWIRE) — Oxford Lane Capital Corp. (NasdaqGS: OXLC) (NasdaqGS: OXLCL) (NasdaqGS: OXLCO) (NasdaqGS: OXLCZ) (NasdaqGS: OXLCN) (NasdaqGS: OXLCI) (NasdaqGS: OXLCG) (NasdaqGS: OXLCM) announced today that it will hold a conference call to discuss its second fiscal quarter earnings on Thursday, November 5, 2026 at 9:00 AM ET. The toll-free dial-in number is 1-800-715-9871, access code number 3024474. There will be a recorded replay of the call available for 30 days after the call. If you are interested in hearing the recording, please dial 1-800-770-2030. The replay pass-code number is 3024474.

About Oxford Lane Capital Corp.

Oxford Lane Capital Corp. is a publicly-traded registered closed-end management investment company principally investing in debt and equity tranches of collateralized loan obligation (“CLO”) vehicles. CLO investments may also include warehouse facilities, which are financing structures intended to aggregate loans that may be used to form the basis of a CLO vehicle.

Contact:
Bruce Rubin
203-983-5280

EL MONTE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) — GigaCloud Technology Inc (Nasdaq: GCT) (“GigaCloud” or the “Company”), a pioneer of global end-to-end B2B technology solutions for large parcel merchandise, today announced that it will report financial results for the 2026 third quarter ended September 30, 2026 before the market opens on Thursday, November 5, 2026. The Company will host a conference call to discuss its financial results on the same day at 8:00 AM Eastern Time.

To access the conference call, participants should pre-register here to receive the dial-in information and a unique PIN. All participants are encouraged to dial-in 15 minutes prior to the conference call’s start time.

A live and archived webcast of the conference call will be accessible on the Company’s investor relations website at https://investors.gigacloudtech.com/news-events/events.

About GigaCloud Technology Inc
GigaCloud Technology Inc is a pioneer of global end-to-end B2B technology solutions for large parcel merchandise. The Company’s B2B ecommerce platform, which it refers to as the “GigaCloud Marketplace,” integrates everything from discovery and payments to logistics tools into one easy-to-use platform. The Company’s global marketplace seamlessly connects manufacturers, primarily in Asia, with resellers, primarily in the U.S., Asia and Europe, to execute cross-border transactions with confidence, speed and efficiency. The Company offers a truly comprehensive solution that transports products from the manufacturer’s warehouse to the end customer’s doorstep, all at one fixed price. The Company first launched its marketplace in January 2019 by focusing on the global furniture market and has since expanded into additional categories such as home appliances and fitness equipment. For more information, please visit the Company’s website: https://investors.gigacloudtech.com/

For investor and media inquiries, please contact:

GigaCloud Technology Inc.
ir@gigacloudtech.com
Pondel Wilkinson Inc.
Laurie Berman (Investors)	Todd Kehrli (Investors)
Lberman@pondel.com	Tkehrli@pondel.com
George Medici (Media)
gmedici@pondel.com

• BlackLine partners with S3NS to expand its services on a trusted cloud in France, addressing stringent data residency and regulatory requirements.
• Thales becomes the first customer to deploy BlackLine’s platform on S3NS’s PREMI3NS trusted cloud.
• The partnership expands BlackLine’s secure infrastructure options, enabling regulated organizations to adopt AI-powered financial operations with greater data control.

PARIS and LOS ANGELES, Oct. 29, 2026 (GLOBE NEWSWIRE) — BlackLine, Inc. (Nasdaq: BL), the Agentic Financial Operations Platform™ for the Office of the CFO, and S3NS, a joint venture controlled by Thales in partnership with Google Cloud, today jointly announced their partnership in France for a new offering hosted on a trusted cloud infrastructure, further expanding BlackLine’s European cloud footprint. This strategic alliance enables organizations with stringent data residency and sovereignty requirements to modernize financial operations while maintaining greater control over where and how their data is managed.

Thales, a global leader in Defense, Aerospace, Cyber, and Digital, will be the first customer to implement BlackLine’s platform on this new infrastructure. The platform will run on PREMI3NS, the trusted cloud offering from S3NS. To support the rollout, Thales’ digital services division will build and operate the local deployment, highlighting the company’s dual role as both a flagship customer and a key integration partner.

This investment expands BlackLine’s ability to serve organizations operating in highly regulated European environments, where data control, security and regulatory requirements are increasingly important considerations in cloud and AI adoption. “Finance cannot compromise on trust. As AI takes on more consequential work, organizations need confidence not only in the accuracy, transparency, and governance of the technology, but also in where their most sensitive financial data resides and how it is controlled,” said Philippe Omer Decugis, Senior Vice President and General Manager for EMEA at BlackLine. “Consequently, data control and regulatory compliance are becoming an increasingly important part of the AI conversation. With this investment, we are giving organizations a path to put trusted AI to work in financial operations while meeting the stringent sovereignty requirements businesses demand.”

BlackLine’s Agentic Financial Operations Platform™, powered by Studio360 and Verity™ AI, enables finance and accounting teams to unify data, automate complex processes, and orchestrate workflows, across mission-critical financial operations. Its AI agents execute specialized financial tasks, from preparing account reconciliations to matching transactions, while keeping finance leaders firmly in control. The trusted cloud deployment model brings these capabilities to organizations requiring greater control over the location and operation of their financial data.

“Our mission at S3NS is to enable organizations to modernize with leading cloud technologies while meeting the highest requirements for data control and regulatory compliance,” said Cyprien Falque, CEO of S3NS. “By providing the Trusted cloud foundation for BlackLine, we are creating an environment where organizations can adopt advanced financial technology while maintaining the control and protections their most sensitive workloads require.”

“Data sovereignty isn’t optional for an organization like Thales, it’s foundational. Being the first to implement BlackLine’s trusted cloud offering reflects our commitment to bringing advanced AI-driven finance capabilities into our operations without compromising on the security and control our business demands,” said Stéphanie Pétris, VP Group Finance Transformation at Thales.

This new French offering with S3NS builds on BlackLine’s broader investment in security, governance and trusted AI, including its ISO/IEC 42001:2023 certification for its Artificial Intelligence Management System. It is also part of BlackLine’s continued expansion of its global cloud footprint and trusted infrastructure, supporting customers as they scale digital finance and AI across increasingly complex environments.

About BlackLine
BlackLine (Nasdaq: BL) is the trust infrastructure for the AI era of finance: a future where finance drives the agentic era with intelligence, integrity, and trust rising together. The BlackLine Agentic Financial Operations Platform™, powered by Studio360 and Verity™ AI, is where the Office of the CFO scales AI across Record-to-Report, Invoice- to-Cash, and the processes where finance owns the controls and demands integrity at every step. By unifying data, embedding AI, and engineering trust into every action, BlackLine moves finance and accounting beyond reporting on the business to orchestrating it in real time. Supported by industry-leading R&D investment and world-class security practices, nearly 4,300 customers across multiple industries partner with BlackLine to lead their organizations into the future. For more information, visit blackline.com.

About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies for the Defense, Aerospace, and Cyber & Digital sectors. Its portfolio of innovative products and services helps address several major challenges: sovereignty, security, sustainability and inclusion. The Group allocates €4.5 billion per year to Research & Development in key areas, particularly for critical environments, such as Artificial Intelligence, Cybersecurity, Quantum and Cloud technologies. Thales has more than 85,000 employees in 65 countries. In 2025, the Group generated sales of €22.1 billion.

About S3NS
An alliance between Thales, a global leader in data protection and cybersecurity, and Google Cloud, one of the world’s leading cloud technology providers, S3NS offers public institutions and private companies—seeking to further protect their most sensitive data—highly secure public cloud solutions to support their transition to a trusted cloud, in compliance with the SecNumCloud framework defined by ANSSI, the French National Agency for the Security of Information Systems. S3NS is a company incorporated under French law and wholly controlled by Thales.

Media Contact
Marion Bonnet, Thales and S3NS Media Relations Manager
Marion.bonnet@thalesgroup.com
+33 6 60 38 48 92

Media Contact
David Brightman, VP Brand & Corporate, BlackLine
Media.Relations@BlackLine.com